Dupixent drives a larger share of Sanofi's revenue, with atopic dermatitis, asthma, and CRSwNP as core indications. Learn ...

For the first time, Eupraxia is reporting 24-week data on symptom response from the highest dose cohort in the open label, Phase 1b/2a portion of the RESOLVE trial. The data is important because it is ...

Leading allergy medical societies and patient advocacy groups highlight path forward to advance food allergy prevention, treatment, and managementWashington, DC, March 19, 2026 (GLOBE NEWSWIRE) -- The ...

A Genoa family is using their experience with a chronic condition to help other children better understand what they’re going ...

A Genoa family is using their experience with a chronic condition to help other children better understand what they’re going through. After their son Boden was diagnosed with eosinophilic esophagitis ...

Detailed price information for Eupraxia Pharmaceuticals Inc (EPRX-Q) from The Globe and Mail including charting and trades.

The World Health Organization also recommends using a z-score for diagnosing faltering weight, in addition to growth charts.

Seasonal allergies are nothing to sniff at. Spring allergy season is worsening with each passing year, as winds carrying ...

A Topeka boy is marking what may be one of the rarest birthdays in the city this week, turning 13 years old on March 13 — having been born on March 13, 2013.

Eupraxia Pharmaceuticals Inc. (EPRX) garnered retail attention on Tuesday after the biotech company reported positive data ...

On November 13, 2025, the Company announced additional 52-week follow-up data from the RESOLVE trial in eosinophilic esophagitis (“EoE”) demonstrating consistent results after dosing with EP-104GI.

Artificial Intelligence (AI) chatbots have been found telling users to push cloves of garlic up their bum as a medical remedy ...